💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Venetoclax

CHEMBL3137309 Phase 4 Approved Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
868.4 g/mol
LogP
8.2
Phase
4

This targeted oral therapy works by blocking BCL-2, a protein that prevents cancer cells from dying, and is used to treat certain types of leukemia (particularly chronic lymphocytic leukemia and acute myeloid leukemia) when combined with other medications. A potentially serious side effect called tumor lysis syndrome can occur at the start of treatment as cancer cells die rapidly, so the dose is gradually increased and patients require careful monitoring and hydration. It is a significant advance for blood cancers that overexpress BCL-2.

Molecular Weight

868.4000 g/mol

LogP

8.20

TPSA

183.00 Ų

Lipinski RO5

Fail

Therapeutic Areas

Age-Related Macular Degeneration Alzheimer's Disease Anesthesiology Asthma Atopic Dermatitis Atrial Fibrillation Benign Prostatic Hyperplasia Bipolar Disorder Bladder Cancer Breast Cancer Cardiovascular Disease Chronic Kidney Disease Chronic Obstructive Pulmonary Disease Chronic Pain Colorectal Cancer Deep Vein Thrombosis / Pulmonary Embolism Dermatology Endocrinology Endometriosis Epilepsy Gastroenterology Gastroesophageal Reflux Disease Generalized Anxiety Disorder Glaucoma Gout Heart Failure Hematology Hepatitis C Hepatology HIV/AIDS Hyperlipidemia Hypertension Immunology Infectious Disease Inflammatory Bowel Disease Insomnia Leukemia Lymphoma Major Depressive Disorder Malaria Melanoma Migraine Multiple Sclerosis Nephrology Neurology Non-Alcoholic Fatty Liver Disease Non-Small Cell Lung Cancer Obesity Obstetrics & Gynecology Oncology Ophthalmology Osteoporosis Ovarian Cancer Pain Management Pancreatic Cancer Parkinson's Disease Prostate Cancer Psoriasis Psychiatry Respiratory Disease Rheumatoid Arthritis Rheumatology Schizophrenia Stroke Systemic Lupus Erythematosus Thyroid Cancer Transplant Medicine Tuberculosis Type 2 Diabetes Urology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1

                

                

                
                

                    
InChI

                    
InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)

                

                

                

                    
                    

                        
Molecular Formula

                        
C45H50ClN7O7S

                    

                    
                    

                        
HBD / HBA

                        
3 / 11

                    

                    
                    

                        
Rotatable Bonds

                        
12

                    

                    
                    
                    

                        
Heavy Atoms

                        
61

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Frequently Asked Questions

                

                    
                    

                        
                        

                            
This targeted oral therapy works by blocking BCL-2, a protein that prevents cancer cells from dying, and is used to treat certain types of leukemia (particularly chronic lymphocytic leukemia and acute myeloid leukemia) when combined with other medications. A potentially serious side effect called tumor lysis syndrome can occur at the start of treatment as cancer cells die rapidly, so the dose is gradually increased and patients require careful monitoring and hydration. It is a significant advance for blood cancers …

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Venetoclax is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3137309.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 49846579.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Medical Disclaimer

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.